Genovese MC, et al. - Authors assessed the safety and maintenance of effiectiveness with ABT-122, a bi-specific monoclonal antibody targeting TNF and IL-17A, in patients with rheumatoid arthritis (RA) or PsA in open-label, 24-week extensions [open-label extensions (OLEs)] of 12-week, randomized, double-blind studies. Adverse events (AEs) and laboratory parameters were included in the safety assessments. For up to 36 weeks, acceptable tolerability and maintenance of efficacy in patients with RA or PsA receiving background MTX was demonstrated by ABT-122.